{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:37:02Z","timestamp":1771511822670,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>We aimed to compare the changes in SARS-CoV-2 spike protein antibody titres based on age group and sex using paired blood sampling after vaccination in association with the presence of nucleocapsid protein antibody.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>All participants were healthcare workers at Yao Municipal Hospital in Osaka who voluntarily provided peripheral blood samples (n\u2009=\u2009636, men\/women 151\/485, mean age 45\u00a0years). We investigated the serial changes in SARS-CoV-2 spike protein antibody titres at 1 and 7\u00a0months after the second vaccination regarding their relationship with sex and age group. At 7\u00a0months, we also examined anti-nucleocapsid assays. Antibody titres were shown as logarithmic values and the differences were assessed using a paired or unpaired student\u2019s t-test as appropriate.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among participants younger than 30\u00a0years, the antibody titres of spike protein were significantly higher in women one (p\u2009=\u20090.005) and seven (p\u2009=\u20090.038) months after vaccination. However, among those aged 30\u201349\u00a0years, the antibody titres were not different between the sexes at either follow-up time point. In contrast, among those aged 50\u201359\u00a0years, between-sex differences in antibody titres were observed only at 7\u00a0months, which was associated with a significant reduction in men. A significant negative correlation was observed between the antibody titres for spike protein at both time points in participants with positive nucleocapsid protein antibody at 7\u00a0months (r\u2009=\u2009\u2212\u00a00.467, p\u2009=\u20090.043), although a significant positive correlation was observed in those with negative results (r\u2009=\u20090.645, p\u2009&lt;\u20090.001),<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Between-sex differences in SARS-CoV-2 spike protein antibody titres by paired blood sampling at different time points after vaccination depended on age group. The presence of nucleocapsid protein antibody was associated with changes in spike protein antibody titres after vaccination.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07695-7","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T09:02:44Z","timestamp":1661504564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Age- and sex-based changes in spike protein antibody status after SARS-CoV-2 vaccination and effect of past-infection in healthcare workers in Osaka"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0268-9417","authenticated-orcid":false,"given":"Shiro","family":"Hoshida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Koeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yo","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeyuki","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,26]]},"reference":[{"key":"7695_CR1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114583","volume":"385","author":"EG Levin","year":"2021","unstructured":"Levin EG, Lustig Y, Cohen C, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med. 2021;385: e84. https:\/\/doi.org\/10.1056\/NEJMoa2114583.","journal-title":"N Engl J Med"},{"key":"7695_CR2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114228","volume":"385","author":"Y Goldberg","year":"2021","unstructured":"Goldberg Y, Mandel M, Bar-On YM, et al. Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med. 2021;385: e85. https:\/\/doi.org\/10.1056\/NEJMoa2114228.","journal-title":"N Engl J Med"},{"key":"7695_CR3","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/S2213-2600(21)00220-4","volume":"9","author":"Y Lustig","year":"2021","unstructured":"Lustig Y, Sapir E, Regev-Yochay G, et al. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lancet Respir Med. 2021;9:999\u20131009. https:\/\/doi.org\/10.1016\/S2213-2600(21)00220-4.","journal-title":"Lancet Respir Med"},{"key":"7695_CR4","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1002\/jmv.26605.(Epub2020Nov1)","volume":"93","author":"E Criscuolo","year":"2021","unstructured":"Criscuolo E, Diotti RA, Strollo M, et al. Weak correlation between antibody titres and neutralizing activity in sera from SARS-CoV-2 infected subjects. J Med Virol. 2021;93:2160\u20137. https:\/\/doi.org\/10.1002\/jmv.26605.(Epub2020Nov1).","journal-title":"J Med Virol"},{"key":"7695_CR5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271\u201380. https:\/\/doi.org\/10.1016\/j.cell.2020.02.052.","journal-title":"Cell"},{"key":"7695_CR6","unstructured":"Elecsys. Anti-SARS-CoV-2 S immunoassay for the quantitative determination of antibodies to the SARS-CoV-2 spike protein. Elecsys\u00ae Anti-SARS-CoV-2 S (roche.com)"},{"key":"7695_CR7","doi-asserted-by":"publisher","first-page":"e03149","DOI":"10.1128\/JCM.03149-20.Print","volume":"59","author":"V Higgins","year":"2021","unstructured":"Higgins V, Fabros A, Kulasingam V. Quantitative Measurement of anti-SARS-CoV-2 antibodies: analytical and clinical evaluation. J Clin Microbiol. 2021;59:e03149-e3220. https:\/\/doi.org\/10.1128\/JCM.03149-20.Print.","journal-title":"J Clin Microbiol"},{"key":"7695_CR8","doi-asserted-by":"publisher","DOI":"10.1101\/2021.10.04.21264521","author":"S Jochum","year":"2021","unstructured":"Jochum S, Kirste I, Hortsch S, et al. Clinical utility of Elecsys anti-SARS-CoV-2 S assay in COVID-19 vaccination: an exploratory analysis of the mRNA-1273 phase 1 trial. medRxiv. 2021. https:\/\/doi.org\/10.1101\/2021.10.04.21264521.","journal-title":"medRxiv"},{"key":"7695_CR9","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","volume":"385","author":"SJ Thomas","year":"2021","unstructured":"Thomas SJ, Moreira ED Jr, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med. 2021;385:1761\u201373. https:\/\/doi.org\/10.1056\/NEJMoa2110345.","journal-title":"N Engl J Med"},{"key":"7695_CR10","unstructured":"Elecsys. Anti-SARS-CoV-2 immunoassay for the qualitative detection of antibodies (incl. IgG) against SARS-CoV-2. http:\/\/diagnostics.roche.com\/global\/en\/products\/params\/elecsys-anti-sars-cov-2.html. Basel, Switzerland: Roche Diagnostics."},{"key":"7695_CR11","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1093\/jalm\/jfaa125","volume":"5","author":"AE Merrill","year":"2020","unstructured":"Merrill AE, Jackson JB, Ehlers A, et al. Head-to-head comparison of two SARS-CoV-2 serology assays. J Appl Lab Med. 2020;5:1351\u20137. https:\/\/doi.org\/10.1093\/jalm\/jfaa125.","journal-title":"J Appl Lab Med"},{"key":"7695_CR12","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/S1473-3099(20)30634-4","volume":"20","author":"National SARS-CoV-2 Serology Assay Evaluation Group","year":"2020","unstructured":"National SARS-CoV-2 Serology Assay Evaluation Group. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infect Dis. 2020;20:1390\u2013400. https:\/\/doi.org\/10.1016\/S1473-3099(20)30634-4.","journal-title":"Lancet Infect Dis"},{"key":"7695_CR13","doi-asserted-by":"publisher","DOI":"10.1128\/Spectrum.00391-21","volume":"9","author":"N Allen","year":"2021","unstructured":"Allen N, Brady M, Carrion Martin AI, et al. SARS-CoV-2 antibody testing in health care workers: a comparison of the clinical performance of three commercially available antibody assays. Microbiol Spectr. 2021;9: e0039121. https:\/\/doi.org\/10.1128\/Spectrum.00391-21.","journal-title":"Microbiol Spectr"},{"key":"7695_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246536","volume":"16","author":"M Wakita","year":"2021","unstructured":"Wakita M, Idei M, Saito K, et al. Comparison of the clinical performance and usefulness of five SARS-CoV-2 antibody tests. PLoS ONE. 2021;16: e0246536. https:\/\/doi.org\/10.1371\/journal.pone.0246536.","journal-title":"PLoS ONE"},{"key":"7695_CR15","doi-asserted-by":"publisher","DOI":"10.1101\/2021.06.25.21259544","author":"SAA Coggins","year":"2021","unstructured":"Coggins SAA, Laing ED, Olsen CH, et al. Adverse effects and\u00a0antibody\u00a0titers\u00a0in response to the BNT162b2 mRNA\u00a0COVID-19\u00a0vaccine\u00a0in a prospective study of healthcare workers. medRxiv. 2021. https:\/\/doi.org\/10.1101\/2021.06.25.21259544.","journal-title":"medRxiv."},{"key":"7695_CR16","doi-asserted-by":"publisher","first-page":"817345","DOI":"10.3389\/fimmu.2022.817345","volume":"13","author":"S Hosseinian","year":"2022","unstructured":"Hosseinian S, Powers K, Vasudev M, et al. Persistence of SARS-CoV-2 antibodies in vaccinated health care workers analyzed by coronavirus antigen microarray. Front Immunol. 2022;13:817345. https:\/\/doi.org\/10.3389\/fimmu.2022.817345.","journal-title":"Front Immunol"},{"key":"7695_CR17","doi-asserted-by":"publisher","first-page":"827306","DOI":"10.3389\/fimmu.2022.827306","volume":"13","author":"JH Choi","year":"2022","unstructured":"Choi JH, Kim YR, Heo ST, et al. Healthcare workers in South Korea Maintain a SARS-CoV-2 antibody response six months after receiving a second dose of the BNT162b2 mRNA vaccine. Front Immunol. 2022;13:827306. https:\/\/doi.org\/10.3389\/fimmu.2022.827306.","journal-title":"Front Immunol"},{"key":"7695_CR18","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1001\/jama.2021.11656","volume":"326","author":"TA Bates","year":"2021","unstructured":"Bates TA, Leier HC, Lyski ZL, et al. Age-dependent neutralization of SARS-CoV-2 and P.1 variant by vaccine immune serum samples. JAMA. 2021;326:868\u20139. https:\/\/doi.org\/10.1001\/jama.2021.11656.","journal-title":"JAMA"},{"key":"7695_CR19","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/S0140-6736(21)00502-X.(Epub2021Feb25)","volume":"397","author":"M Prendecki","year":"2021","unstructured":"Prendecki M, Clarke C, Brown J, et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. Lancet. 2021;397:1178\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(21)00502-X.(Epub2021Feb25).","journal-title":"Lancet"},{"key":"7695_CR20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.19741","volume":"4","author":"M Anderson","year":"2021","unstructured":"Anderson M, Stec M, Rewane A, et al. SARS-CoV-2 antibody responses in infection-naive or previously infected individuals after 1 and 2 doses of the BNT162b2 vaccine. JAMA Netw Open. 2021;4: e2119741. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.19741.","journal-title":"JAMA Netw Open"},{"key":"7695_CR21","doi-asserted-by":"publisher","first-page":"eabf4063","DOI":"10.1126\/science.abf4063","volume":"371","author":"JM Dan","year":"2021","unstructured":"Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371:eabf4063. https:\/\/doi.org\/10.1126\/science.abf4063.","journal-title":"Science"},{"key":"7695_CR22","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.chom.2021.04.015","volume":"29","author":"K Vanshylla","year":"2021","unstructured":"Vanshylla K, Di Cristanziano V, Kleipass F, et al. Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans. Cell Host Microbe. 2021;29:917\u201329. https:\/\/doi.org\/10.1016\/j.chom.2021.04.015.","journal-title":"Cell Host Microbe"},{"key":"7695_CR23","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(21)00675-9.(Epub2021Apr9)","volume":"397","author":"VJ Hall","year":"2021","unstructured":"Hall VJ, Foulkes S, Charlett A, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet. 2021;397:1459\u201369. https:\/\/doi.org\/10.1016\/S0140-6736(21)00675-9.(Epub2021Apr9).","journal-title":"Lancet"},{"key":"7695_CR24","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2034545.(Epub2020Dec23)","volume":"384","author":"SF Lumley","year":"2021","unstructured":"Lumley SF, O\u2019Donnell D, Stoesser NE, et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N Engl J Med. 2021;384:533\u201340. https:\/\/doi.org\/10.1056\/NEJMoa2034545.(Epub2020Dec23).","journal-title":"N Engl J Med"},{"key":"7695_CR25","doi-asserted-by":"publisher","first-page":"e00084","DOI":"10.1128\/CMR.00084-18","volume":"32","author":"P Zimmermann","year":"2019","unstructured":"Zimmermann P, Curtis N. Factors that influence the immune response to vaccination. Clin Microbiol Rev. 2019;32:e00084-e118. https:\/\/doi.org\/10.1128\/CMR.00084-18.","journal-title":"Clin Microbiol Rev"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07695-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07695-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07695-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T09:04:51Z","timestamp":1661504691000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07695-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,26]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["7695"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07695-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,26]]},"assertion":[{"value":"13 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the research ethics committee of the Yao Municipal Hospital for COVID-19 (YMH 120321-140). This study was performed according to the Declaration of Helsinki. Informed consent was obtained in an opt-out form on the institution\u2019s website. The institutional ethics committee approved this informed consent plan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the submission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"709"}}